Search clinical trials for: Placebo to MK-0873

Total 1556 results

Merck Sharp & Dohme LLC

Terminated

An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)

Lung Diseases | Pulmonary Disease, Chronic Obstructive
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)

Plaque Psoriasis
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)

Sarcopenia
Merck Sharp & Dohme LLC

Completed

A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)

Rheumatoid Arthritis
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Greece, Israel, Italy, Mexico, New Zealand, Poland, Russian Federation, Sweden, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, Israel, South Africa
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

Psoriasis | Plaque Psoriasis

United States
Merck Sharp & Dohme LLC

Completed

Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)

Primary Insomnia
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
Merck Sharp & Dohme LLC

Completed

A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) (C-SURFER)

Hepatitis C Virus
Merck Sharp & Dohme LLC

Terminated

Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003)

HIV-1 Infection
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

Obesity | Overweight

United States
Advanz Pharma

Completed

A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

Atrial Fibrillation
Merck Sharp & Dohme LLC

Completed

A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)

Parkinson's Disease
Merck Sharp & Dohme LLC

Completed

MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)

Type 2 Diabetes Mellitus
Genentech, Inc.

Completed

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

Urticaria

United States, Germany, Canada
Kissei Pharmaceutical Co., Ltd.

Completed

An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Spinocerebellar Degeneration

Japan
Organon and Co

Completed

A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants

Healthy Volunteer

United States
Novo Nordisk A/S

Completed

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Merck Sharp & Dohme LLC

Completed

A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Completed

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Afferent Pharmaceuticals, Inc.

Completed

A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)

Refractory Chronic Cough
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

Facioscapulohumeral Muscular Dystrophy

United States, Spain, Canada
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)

Dementia | Alzheimer's Disease
Genentech, Inc.

Completed

A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Korea, Republic of, Spain, Taiwan, Bulgaria, Colombia, Argentina, Brazil, Mexico, United Kingdom, Chile, Germany
Organon and Co

Completed

MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)

Hypertension
Merck Sharp & Dohme LLC

Active, not recruiting

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

HIV Infection

United States, Australia, Austria, Canada, Finland, France, Germany, Italy, Japan, Puerto Rico, Spain
Kissei Pharmaceutical Co., Ltd.

Completed

A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Spinocerebellar Degeneration

Japan
Merck Sharp & Dohme LLC

Active, not recruiting

Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

HIV-1 Infection

United States, France, Switzerland
Merck Sharp & Dohme LLC

Completed

A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)

Angina Pectoris | Coronary Heart Disease | Calcitonin Gene-related Peptide Receptor
Merck Sharp & Dohme LLC

Completed

Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

HIV-1 Infection

United States, Australia, Canada, Chile, Colombia, France, Germany, Italy, Japan, Korea, Republic of, Peru, Portugal, Puerto Rico, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders

Healthy Subjects

Germany
Merck Sharp & Dohme LLC

Completed

A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Hypertension | Isolated Systolic Hypertension
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Polysomnography

3

Subscribe